12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RG4934: Development discontinued

Roche disclosed in its 1H12 earnings that it discontinued development of RG4934, which was in Phase I testing for inflammatory diseases....

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >